Clinical Trials · NCT00241423
Effect of Exenatide on 24-Hour Blood Glucose Profile Compared With Placebo in Patients With Type 2 Diabetes
- Phase
- Phase 2
- Recruitment status
- Completed
- Sponsor
- AstraZeneca
- Enrollment
- 30
- Start date
- Oct 2005
- Locations
- 2 sites, United States
- Primary endpoint
- Time-averaged serum glucose during a 24-hour period